Incyte Bolsters Dermatology Ambitions With Vitiligo Approval For Topical Ruxolitinib
Executive Summary
Opzelura, already approved for atopic dermatitis, gives Incyte a second indication for its topical JAK inhibitor. It is the first treatment approved for vitiligo.
You may also be interested in...
Incyte’s Oral JAK1 Inhibitor Shows Potential In Facial, Full Body Vitiligo
After promising Phase IIb 24-week data with povorcitinib, Incyte unveiled 52-week data indicating greater improvement with longer-term therapy and plans to initiate a Phase III trial.
Lilly's Olumiant Is First Drug FDA Approved For Alopecia Areata
The FDA approved baricitinib for the hair loss disorder despite safety concerns with JAK inhibitors. It carries the same warnings on risk of CV events and malignancy as the others in the class.
Almirall Views Vitiligo As Next Dermatology Opportunity
As it prepares to file lebrikizumab for atopic dermatitis, the Spanish group is looking to expand into vitiligo through a collaboration with France’s Inserm Transfert to develop topical therapies for the condition where pale patches develop on the skin caused by the lack of melanin.